299 related articles for article (PubMed ID: 27107490)
1. Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD: A Pilot Clinical Trial.
Cosío BG; Shafiek H; Iglesias A; Yanez A; Córdova R; Palou A; Rodriguez-Roisin R; Peces-Barba G; Pascual S; Gea J; Sibila O; Barnes PJ; Agusti A
Chest; 2016 Jul; 150(1):123-30. PubMed ID: 27107490
[TBL] [Abstract][Full Text] [Related]
2. Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.
Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
Health Technol Assess; 2019 Jul; 23(37):1-146. PubMed ID: 31343402
[TBL] [Abstract][Full Text] [Related]
3. Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD.
Ford PA; Durham AL; Russell RE; Gordon F; Adcock IM; Barnes PJ
Chest; 2010 Jun; 137(6):1338-44. PubMed ID: 20299628
[TBL] [Abstract][Full Text] [Related]
4. Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial.
Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; De Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
JAMA; 2018 Oct; 320(15):1548-1559. PubMed ID: 30326124
[TBL] [Abstract][Full Text] [Related]
5. Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial.
Devereux G; Cotton S; Barnes P; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; De Soyza A; Fielding S; Gompertz S; Haughney J; Lee AJ; McCormack K; McPherson G; Morice A; Norrie J; Sullivan A; Wilson A; Price D
Trials; 2015 Jun; 16():267. PubMed ID: 26058585
[TBL] [Abstract][Full Text] [Related]
6. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial.
Watz H; Tetzlaff K; Wouters EF; Kirsten A; Magnussen H; Rodriguez-Roisin R; Vogelmeier C; Fabbri LM; Chanez P; Dahl R; Disse B; Finnigan H; Calverley PM
Lancet Respir Med; 2016 May; 4(5):390-8. PubMed ID: 27066739
[TBL] [Abstract][Full Text] [Related]
7. Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD.
Cosio BG; Iglesias A; Rios A; Noguera A; Sala E; Ito K; Barnes PJ; Agusti A
Thorax; 2009 May; 64(5):424-9. PubMed ID: 19158122
[TBL] [Abstract][Full Text] [Related]
8. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978].
Sin DD; Man SF; Marciniuk DD; Ford G; FitzGerald M; Wong E; York E; Mainra RR; Ramesh W; Melenka LS; Wilde E; Cowie RL; Williams D; Rousseau R;
BMC Pulm Med; 2006 Feb; 6():3. PubMed ID: 16460562
[TBL] [Abstract][Full Text] [Related]
9. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
Broseghini C; Testi R; Polese G; Tosatto R; Rossi A
Pulm Pharmacol Ther; 2005; 18(2):103-8. PubMed ID: 15649852
[TBL] [Abstract][Full Text] [Related]
10. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD.
Hanania NA
Pulm Pharmacol Ther; 2008; 21(3):540-50. PubMed ID: 18280761
[TBL] [Abstract][Full Text] [Related]
11. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
Larsson K; Janson C; Lisspers K; Jørgensen L; Stratelis G; Telg G; Ställberg B; Johansson G
J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860
[TBL] [Abstract][Full Text] [Related]
12. Regulation of YKL-40 expression by corticosteroids: effect on pro-inflammatory macrophages in vitro and its modulation in COPD in vivo.
Kunz LI; van't Wout EF; van Schadewijk A; Postma DS; Kerstjens HA; Sterk PJ; Hiemstra PS
Respir Res; 2015 Dec; 16():154. PubMed ID: 26696093
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts.
Cheng SL; Lin CH
Int J Chron Obstruct Pulmon Dis; 2016; 11():2341-2348. PubMed ID: 27703344
[TBL] [Abstract][Full Text] [Related]
14. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease.
Sin DD; Man SF; Marciniuk DD; Ford G; FitzGerald M; Wong E; York E; Mainra RR; Ramesh W; Melenka LS; Wilde E; Cowie RL; Williams D; Gan WQ; Rousseau R;
Am J Respir Crit Care Med; 2008 Jun; 177(11):1207-14. PubMed ID: 18310480
[TBL] [Abstract][Full Text] [Related]
15. Inhaled long-acting β2 agonists enhance glucocorticoid receptor nuclear translocation and efficacy in sputum macrophages in COPD.
Haque R; Hakim A; Moodley T; Torrego A; Essilfie-Quaye S; Jazrawi E; Johnson M; Barnes PJ; Adcock IM; Usmani OS
J Allergy Clin Immunol; 2013 Nov; 132(5):1166-73. PubMed ID: 24070494
[TBL] [Abstract][Full Text] [Related]
16. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
17. Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial.
Choudhury AB; Dawson CM; Kilvington HE; Eldridge S; James WY; Wedzicha JA; Feder GS; Griffiths CJ
Respir Res; 2007 Dec; 8(1):93. PubMed ID: 18162137
[TBL] [Abstract][Full Text] [Related]
18. The use of long acting β₂-agonists, alone or in combination with inhaled corticosteroids, in chronic obstructive pulmonary disease (COPD): a risk-benefit analysis.
Cave AC; Hurst MM
Pharmacol Ther; 2011 May; 130(2):114-43. PubMed ID: 21276815
[TBL] [Abstract][Full Text] [Related]
19. Association of blood eosinophils and plasma periostin with FEV1 response after 3-month inhaled corticosteroid and long-acting beta2-agonist treatment in stable COPD patients.
Park HY; Lee H; Koh WJ; Kim S; Jeong I; Koo HK; Kim TH; Kim JW; Kim WJ; Oh YM; Sin DD; Lim SY; Lee SD;
Int J Chron Obstruct Pulmon Dis; 2016; 11():23-30. PubMed ID: 26730185
[TBL] [Abstract][Full Text] [Related]
20. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]